Outcome improvement of cellular cardiomyoplasty using triple therapy: Mesenchymal stem cell+erythropoietin+vascular endothelial growth factor

Tavakoli, F. and Ostad, S.N. and Khori, V. and Alizadeh, A.M. and Sadeghpour, A. and Darbandi-Azar, A. and Haghjoo, M. and Zare, A. and Nayebpour, M. (2013) Outcome improvement of cellular cardiomyoplasty using triple therapy: Mesenchymal stem cell+erythropoietin+vascular endothelial growth factor. European Journal of Pharmacology, 714 (1-3). pp. 456-463.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


To improve cellular cardiomyoplasty efficacy after myocardial infarction (MI), we postulated that combining mesenchymal stem cells (MSCs) transplantation with anti-apoptotic and angiogenic effects of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) may provide better prognosis in an infarcted heart 48 rats, underwent left anterior descending artery ligation, were divided into eight groups and treated as follows: Group 1: MSC+EPO+VEGF, Group 2: MSC+EPO, Group 3: MSC+VEGF, Group 4: MSC, Group 5: EPO+VEGF, Group 6: EPO, Group 7: VEGF and Group 8: Control. After MI induction, EPO and VEGF were injected subcutaneously at the dose of 3000 U/kg and 3 mg/kg respectively. MSCs were transplanted one week after MI. In the fourteenth and sixteenth days after infarction, EPO was injected again. Echocardiography demonstrated that all treatments improved left ventricular function significantly (before vs. after treatment) but in control group ejection fraction deteriorated over the 2-months period. Percent of ejection fraction recovery in all treatment groups were significantly greater than control (P<0.05). Compared with the control group, all treatments attenuated cell death in peri-infarct areas significantly, except groups 6 and 7. Vascular density of all treatment groups were more than control group but this superiority was statistically significant only in group1 (P<0.01). All of our treatments had beneficial effects to some extent but MSC transplantation combined with EPO and VEGF administration resulted in superior therapeutic outcome in enhancing cell survival and neovascularization. © 2013 Elsevier B.V. All rights reserved.

Item Type: Article
Additional Information: cited By 7
Uncontrolled Keywords: erythropoietin; vasculotropin, angiogenesis; animal experiment; animal model; animal tissue; apoptosis; article; cardiomyoplasty; cellular cardiomyoplasty; controlled study; coronary artery ligation; echocardiography; heart infarction; heart left ventricle ejection fraction; heart left ventricle function; heart muscle necrosis; left anterior descending coronary artery; male; mesenchymal stem cell transplantation; nonhuman; priority journal; rat, Erythropoietin; Heart failure; Mesenchymal stem cell; Myocardial infarction; Vascular endothelial growth factor, Animals; Apoptosis; Cardiomyoplasty; Cell Culture Techniques; Cell Separation; Combined Modality Therapy; Electrocardiography; Erythropoietin; Male; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocytes, Cardiac; Necrosis; Neovascularization, Physiologic; Phenotype; Prognosis; Rats; Rats, Wistar; Treatment Outcome; Vascular Endothelial Growth Factor A
Subjects: WG Cardiovascular System
Depositing User: somayeh pourmorteza
Date Deposited: 26 Feb 2019 08:30
Last Modified: 26 Feb 2019 08:30
URI: http://eprints.iums.ac.ir/id/eprint/9759

Actions (login required)

View Item View Item